JOURNAL OF PEDIATRIC RESEARCH, cilt.6, sa.3, ss.197-202, 2019 (ESCI)
Aim: Despite dramatic progress in the treatment of pediatric solid tumors in the last 3 decades, confronting a relapsed or refractory patient is still challenging. We report our experience of refractory/relapsed pediatric solid tumor patients treated with vincristin + topotecan + cyclophosphamide (VTC) as a salvage therapy.